Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621605 · ClinicalTrials.gov registry record · Phase 1
A Phase1 Study of VIB9600
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03621605 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 24 participants.
The verdict
NCT03621605, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Overall design: Single-center, randomized, blinded, placebo-controlled single- and multiple-ascending dose study in healthy adult subjects.
Interventions
- DRUG Placebos
- BIOLOGICAL VIB9600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2019-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03621605
The ClinicalTrials.gov registry entry for NCT03621605 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03621605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03621605 about?
NCT03621605 is a clinical study titled "A Phase1 Study of VIB9600". Overall design: Single-center, randomized, blinded, placebo-controlled single- and multiple-ascending dose study in healthy adult subjects.
What is the current status of trial NCT03621605?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-08-14. Estimated completion is 2019-04-08.
What interventions are being tested in trial NCT03621605?
The interventions under investigation include: Placebos (DRUG), VIB9600 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03621605?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.